Why is cycloserine not reimbursed by medical insurance?

Cycloserine (Cycloserine) is an important antibiotic used for drug-resistant tuberculosis or complicated pulmonary infections. It has been on the market in China for many years and is included in Category B of the National Medical Insurance Directory. However, many patients still mistakenly believe that "cycloserine is not reimbursed" or "cannot actually enjoy medical insurance." The reasons for this misunderstanding are closely related to drug classification, medical insurance payment policies, and implementation differences in different regions. Although the drugs themselves are included in the medical insurance, there are often big differences in whether they can be reimbursed locally and whether the reimbursement ratio can meet patients' expectations. This is what patients need to focus on at present.

Cycloserine is a Class B medical insurance drug, which means that it has been included in the national medical insurance directory. However, Class B drugs require patients to pay a certain percentage out of pocket. The reimbursement ratio varies from region to region, and some areas may require patients to pay a higher proportion out of pocket. Therefore, many people mistakenly believe that"cannot be reimbursed." Therefore, "entering into medical insurance" does not mean "full reimbursement." Instead, in accordance with policy regulations, local medical insurance departments jointly set reimbursement standards based on drug prices, hospital grades, and treatment paths. Therefore, the reimbursement experience for patients in different places is different.

Cycloserine is mainly used in special infection situations such as drug-resistant tuberculosis. Its use usually needs to be prescribed in designated hospitals, tuberculosis specialist hospitals or infectious disease specialists under the medical insurance route. Some areas have implemented strict management systems for special anti-tuberculosis drugs, which require clear evidence of drug resistance and a prescription process before they can be included in medical insurance reimbursement. If the patient uses it in a non-designated hospital or does not follow the infectious disease management process, "medical insurance will not pay" may occur, further deepening the patient's misunderstanding of "cannot be reimbursed".

In addition, drug supply channels will also affect the medical insurance experience. Designated hospitals in some areas may not always stock cycloserine, but need to make an appointment to purchase or deploy it on demand. In this case, medical insurance can only be used in designated institutions. If patients purchase it from retail pharmacies or third-party channels, they will not be able to enjoy medical insurance payment, which will create the impression that "medical insurance does not cover". This is especially common in patients on long-term treatment.

Reference materials:https://en.wikipedia.org/wiki/Cycloserine